Volume 7 Issue 6, Jun 2022

ISSN: 2095-9907 

EISSN: 2059-23635 

2023 impact factor 40.8 

 (Clarivate Analytics, 2024)
Volume 7 Issue 6, Jun 2022:
Research Highlight
Nivolumab plus ipilimumab: a potential regimen to rewrite treatment guidelines for ESCC
Yuejun Luo,Nan Sun &Jie He  ORCID: orcid.org/0000-0002-0285-5403